Category: Press Release - Page 32 - Psychedelic Alpha

Read more about the article FILAMENT HEALTH ANNOUNCES CLINICAL TRIAL APPROVAL IN PARTNERSHIP WITH PSYCHIATRIC CENTRE COPENHAGEN

FILAMENT HEALTH ANNOUNCES CLINICAL TRIAL APPROVAL IN PARTNERSHIP WITH PSYCHIATRIC CENTRE COPENHAGEN

Post published:January 20, 2023
Post category:Press Release

Read more about the article Numinus Wellness Inc. Reports Q1 2023 Results

Numinus Wellness Inc. Reports Q1 2023 Results

Post published:January 19, 2023
Post category:Press Release

Read more about the article PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome

PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome

Post published:January 18, 2023
Post category:Press Release

Read more about the article Optimi Health Expands Functional Mushroom Sales Network With Additional Brokers, Distribution Agreements

Optimi Health Expands Functional Mushroom Sales Network With Additional Brokers, Distribution Agreements

Post published:January 18, 2023
Post category:Press Release

Read more about the article Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study

Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study

Post published:January 17, 2023
Post category:Press Release

Read more about the article Israel-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study for Cocaine Addiction Treatment

Israel-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study for Cocaine Addiction Treatment

Post published:January 17, 2023
Post category:Press Release

Read more about the article First Patient Dosed in Small Pharma’s Phase I Study Exploring Intramuscular Administration of SPL026

First Patient Dosed in Small Pharma’s Phase I Study Exploring Intramuscular Administration of SPL026

Post published:January 15, 2023
Post category:Press Release

Read more about the article Revive Therapeutics legt aktualisiertes Informationspaket zur Unterstützung der bevorstehenden Sitzung des Typs C vor, die von der FDA für die geänderte Prüfplanvereinbarung der klinischen Phase-III-Studie für Bucillamin zur Behandlung von COVID-19 genehmigt wurde

Revive Therapeutics legt aktualisiertes Informationspaket zur Unterstützung der bevorstehenden Sitzung des Typs C vor, die von der FDA für die geänderte Prüfplanvereinbarung der klinischen Phase-III-Studie für Bucillamin zur Behandlung von COVID-19 genehmigt wurde

Post published:January 15, 2023
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board

Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board

Post published:January 15, 2023
Post category:Press Release

Read more about the article Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation

Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation

Post published:January 13, 2023
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.